Literature DB >> 20868630

Different effects of mirtazapine and venlafaxine on brain activation: an open randomized controlled fMRI study.

Thomas Frodl1, Johanna Scheuerecker, Veronika Schoepf, Jennifer Linn, Nikolaos Koutsouleris, Arun L W Bokde, Harald Hampel, Hans-Jürgen Möller, Hartmut Brückmann, Martin Wiesmann, Eva Meisenzahl.   

Abstract

OBJECTIVE: Antidepressants with different mechanisms of action might have different effects on brain functions. The aim of the study was therefore to investigate effects of 2 antidepressants on brain activation and to identify predictors for therapy response.
METHOD: Twenty-four untreated patients with major depressive disorder (according to Structured Clinical Interview for DSM-IV) were enrolled in a prospective, randomized, 4-week trial with mirtazapine and venlafaxine. Functional magnetic resonance imaging (fMRI) was performed at baseline and after 4 weeks in the patients and in 15 healthy controls. The primary outcome measure was fMRI blood-oxygen-level dependence (BOLD) activation. The patients were recruited in 2007 and 2008.
RESULTS: Comparison between patients and controls revealed that emotional face matching elicited enhanced activation in the anterior cingulate cortex (ACC), dorsomedial prefrontal cortex, dorsolateral prefrontal cortex, and basal ganglia in patients. During treatment, a significant decrease of BOLD responses was seen in the hippocampus, basal ganglia, thalamus, and cerebellum of venlafaxine-treated patients, and a significant increase in BOLD responses was seen in the middle cingulate gyrus and supplementary motor area of mirtazapine-treated patients (P < .05, family wise error [FWE] cluster-level corrected). Larger BOLD responses in the left fusiform gyrus at baseline predicted a better response to venlafaxine, and smaller BOLD responses in the right rolandic operculum at baseline predicted a better response to mirtazapine (P < .05, FWE cluster-level corrected).
CONCLUSIONS: These fMRI results indicate that antidepressants with different mechanisms of action have different effects on brain function. It therefore seems that fMRI can be used for therapy evaluation and response prediction and can facilitate the development of new pharmaceuticals. © Copyright 2011 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20868630     DOI: 10.4088/JCP.09m05393blu

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  21 in total

1.  Stroop-related cerebellar and temporal activation is correlated with negative affect and alcohol use disorder severity.

Authors:  Claire E Wilcox; Joshua Clifford; Josef Ling; Andrew R Mayer; Rose Bigelow; Michael P Bogenschutz; J Scott Tonigan
Journal:  Brain Imaging Behav       Date:  2020-04       Impact factor: 3.978

Review 2.  Progress in Elucidating Biomarkers of Antidepressant Pharmacological Treatment Response: A Systematic Review and Meta-analysis of the Last 15 Years.

Authors:  G Voegeli; M L Cléry-Melin; N Ramoz; P Gorwood
Journal:  Drugs       Date:  2017-12       Impact factor: 9.546

3.  The Canadian Biomarker Integration Network in Depression (CAN-BIND): magnetic resonance imaging protocols

Authors:  Glenda M. MacQueen; Stefanie Hassel; Stephen R. Arnott; Addington Jean; Christopher R. Bowie; Signe L. Bray; Andrew D. Davis; Jonathan Downar; Jane A. Foster; Benicio N. Frey; Benjamin I. Goldstein; Geoffrey B. Hall; Kate L. Harkness; Jacqueline Harris; Raymond W. Lam; Catherine Lebel; Roumen Milev; Daniel J. Müller; Sagar V. Parikh; Sakina Rizvi; Susan Rotzinger; Gulshan B. Sharma; Claudio N. Soares; Gustavo Turecki; Fidel Vila-Rodriguez; Joanna Yu; Mojdeh Zamyadi; Stephen C. Strother; Sidney H. Kennedy
Journal:  J Psychiatry Neurosci       Date:  2019-07-01       Impact factor: 6.186

4.  Differential modulation of emotion processing brain regions by noradrenergic and serotonergic antidepressants.

Authors:  Annette Beatrix Brühl; Lutz Jäncke; Uwe Herwig
Journal:  Psychopharmacology (Berl)       Date:  2011-02-26       Impact factor: 4.530

5.  Effect of genetic variant in BICC1 on functional and structural brain changes in depression.

Authors:  Rachel Bermingham; Angela Carballedo; Danuta Lisiecka; Andrew Fagan; Derek Morris; Ciara Fahey; Gary Donohoe; James Meaney; Michael Gill; Thomas Frodl
Journal:  Neuropsychopharmacology       Date:  2012-08-22       Impact factor: 7.853

Review 6.  Molecular, Functional, and Structural Imaging of Major Depressive Disorder.

Authors:  Kai Zhang; Yunqi Zhu; Yuankai Zhu; Shuang Wu; Hao Liu; Wei Zhang; Caiyun Xu; Hong Zhang; Takuya Hayashi; Mei Tian
Journal:  Neurosci Bull       Date:  2016-05-03       Impact factor: 5.203

7.  Effects of citalopram and escitalopram on fMRI response to affective stimuli in healthy volunteers selected by serotonin transporter genotype.

Authors:  Michael E Henry; Tara L Lauriat; Steven B Lowen; Jeffrey H Churchill; Colin A Hodgkinson; David Goldman; Perry F Renshaw
Journal:  Psychiatry Res       Date:  2013-07-09       Impact factor: 3.222

8.  Facial emotion processing in major depression: a systematic review of neuroimaging findings.

Authors:  Anja Stuhrmann; Thomas Suslow; Udo Dannlowski
Journal:  Biol Mood Anxiety Disord       Date:  2011-11-07

Review 9.  Neuroimaging-based biomarkers for treatment selection in major depressive disorder.

Authors:  Boadie W Dunlop; Helen S Mayberg
Journal:  Dialogues Clin Neurosci       Date:  2014-12       Impact factor: 5.986

Review 10.  Diagnostic and therapeutic utility of neuroimaging in depression: an overview.

Authors:  Toby Wise; Anthony J Cleare; Andrés Herane; Allan H Young; Danilo Arnone
Journal:  Neuropsychiatr Dis Treat       Date:  2014-08-19       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.